These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
247 related articles for article (PubMed ID: 2522911)
1. Lymphokine-activated killer-cell function of lymphocytes from peripheral blood, regional lymph nodes and tumor tissues of patients with oral cancer. Tatake RJ; Krishnan N; Rao RS; Fakih AR; Gangal SG Int J Cancer; 1989 Apr; 43(4):560-6. PubMed ID: 2522911 [TBL] [Abstract][Full Text] [Related]
2. Immunoreactivity of lymphocytes from draining lymph nodes, peripheral blood and tumor infiltrates from oral cancer patients. Mukhopadhyaya R; Tatake RJ; Krishnan N; Rao RS; Fakih AR; Naik SL; Gangal SG J Clin Lab Immunol; 1989 Sep; 30(1):21-5. PubMed ID: 2641790 [TBL] [Abstract][Full Text] [Related]
3. The absence of lymphoid suppressor cells in tumor-involved lymph nodes of patients with head and neck cancer. Letessier EM; Sacchi M; Johnson JT; Herberman RB; Whiteside TL Cell Immunol; 1990 Oct; 130(2):446-58. PubMed ID: 2145080 [TBL] [Abstract][Full Text] [Related]
5. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells. Morikawa Y; Watanabe S; Kodama T Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285 [TBL] [Abstract][Full Text] [Related]
6. Different immune functions of peripheral blood, regional lymph node, and tumor infiltrating lymphocytes in lung cancer patients. Nakamura H; Ishiguro K; Mori T Cancer; 1988 Dec; 62(12):2489-97. PubMed ID: 3142676 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-2 mediated regulation of mitogen-activated T cell reactivity from different lymphoid sources in patients with squamous cell carcinoma of the oral cavity. Murali PS; Somasundaram R; Rao RS; Fakih AR; Gangal SG J Oral Pathol Med; 1989 Jul; 18(6):327-32. PubMed ID: 2810131 [TBL] [Abstract][Full Text] [Related]
9. Lymphokine-activated killer cell phenomenon. II. Precursor phenotype is serologically distinct from peripheral T lymphocytes, memory cytotoxic thymus-derived lymphocytes, and natural killer cells. Grimm EA; Ramsey KM; Mazumder A; Wilson DJ; Djeu JY; Rosenberg SA J Exp Med; 1983 Mar; 157(3):884-97. PubMed ID: 6601174 [TBL] [Abstract][Full Text] [Related]
10. Effect of anti-CD3 antibody on the generation of interleukin-2-activated lymphocytes from tumor tissues of gastrointestinal cancer. Ohta T; Kikuchi H; Ogata H; Iwata K; Yoshida K; Katayama K; Watanabe H Cancer; 1992 Aug; 70(4):741-8. PubMed ID: 1386555 [TBL] [Abstract][Full Text] [Related]
11. Functional and phenotypic analysis of lymphocytes in head and neck cancer. Snyderman CH; Heo DS; Johnson JT; D'Amico F; Barnes L; Whiteside TL Arch Otolaryngol Head Neck Surg; 1991 Aug; 117(8):899-905. PubMed ID: 1832546 [TBL] [Abstract][Full Text] [Related]
12. Generation and expansion of lymphokine-activated killer cells from lymph node lymphocytes in human lung cancer. Yano T; Yasumoto K; Nomoto K Eur J Cancer Clin Oncol; 1989 Feb; 25(2):201-8. PubMed ID: 2784761 [TBL] [Abstract][Full Text] [Related]
13. Distinct cytotoxicity against neuroblastoma cells of peripheral blood and tumor-infiltrating lymphocytes from patients with neuroblastoma. Kataoka Y; Matsumura T; Yamamoto S; Sugimoto T; Sawada T Cancer Lett; 1993 Sep; 73(1):11-21. PubMed ID: 8402593 [TBL] [Abstract][Full Text] [Related]
14. Characterization of lymphokine-activated killer cells from peripheral blood and lymph nodes of non-Hodgkin's lymphoma patients. Nadkarni JJ; Jhaver KG; De AK; Soman CS; Nadkarni KS Neoplasma; 1993; 40(1):15-20. PubMed ID: 8350943 [TBL] [Abstract][Full Text] [Related]
15. Functional character and augmentation of lymphocytes in regional lymph nodes of patients with lung cancer. Watanabe Y; Hashizume Y; Shimizu J; Yoshida M; Watanabe S; Iwa T; Sakai S; Migita S; Sato H; Murayama T Am Rev Respir Dis; 1990 Oct; 142(4):769-74. PubMed ID: 2221581 [TBL] [Abstract][Full Text] [Related]
16. Identification and selection of human lymphokine activated killer cell effectors and novel recycling intermediates by unique light-scattering properties. Loudon WG; Abraham SR; Owen-Schaub LB; Hemingway LL; Hemstreet GP; DeBault LE Cancer Res; 1988 Apr; 48(8):2184-92. PubMed ID: 3258186 [TBL] [Abstract][Full Text] [Related]
17. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells. Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523 [TBL] [Abstract][Full Text] [Related]
18. Phenotypic characterization of lymphokine-activated killer cells from human lymph node lymphocytes. Yano T; Murata M; Ishida T; Mitsudomi T; Kimura G; Sugimachi K; Nomoto K Cell Immunol; 1989 Sep; 122(2):578-84. PubMed ID: 2788522 [TBL] [Abstract][Full Text] [Related]
19. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes. Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716 [TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]